Ismelin Side Effects
Generic Name: guanethidine
Note: This page contains information about the side effects of guanethidine. Some of the dosage forms included on this document may not apply to the brand name Ismelin.
Not all side effects for Ismelin may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to guanethidine: oral tablet
In addition to its needed effects, some unwanted effects may be caused by guanethidine (the active ingredient contained in Ismelin). In the event that any of these side effects do occur, they may require medical attention.
If any of the following side effects occur while taking guanethidine, check with your doctor or nurse as soon as possible:More common
- Swelling of feet or lower legs
- Chest pain
- shortness of breath
Some of the side effects that can occur with guanethidine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Diarrhea or increase in bowel movements
- dizziness, lightheadedness, or fainting, especially when getting up from a lying or sitting position
- sexual problems in males
- slow heartbeat
- stuffy nose
- unusual tiredness or weakness
- Blurred vision
- drooping eyelids
- dryness of mouth
- loss of hair on scalp
- muscle pain or tremors
- nausea or vomiting
- nighttime urination
- skin rash
For Healthcare Professionals
Applies to guanethidine: oral tablet
The risk of orthostatic hypotension, sometimes followed by syncope, is greatest within the first 10 minutes after dosing, early in the morning, and in hypovolemic patients. It is accentuated by alcohol, hot weather, or exercise--all of which are associated with peripheral vasodilation. The manufacturer recommends that guanethidine (the active ingredient contained in Ismelin) be gradually withdrawn over at least two weeks prior to administration of general anesthetics to avoid cardiovascular collapse during induction.
Cardiovascular side effects can result from excessive sympathetic blockade or a relative increase in parasympathetic tone. Orthostatic hypotension is reported in approximately 15% of patients, some of whom experience syncope.
Unopposed or excessive parasympathetic tone can cause excessive bradycardia in rare cases. This may cause serious problems in patients with underlying sinus node dysfunction.
Guanethidine can cause generalized edema in 10% to 15% of patients. Some patients with preexisting congestive heart failure do not tolerate this, and require concomitant diuretic therapy.
Gastrointestinal side effects are also related to increased parasympathetic tone. Diarrhea is reported in 11% of patients, some of whom discontinued therapy because of it. Dry mouth or parotid tenderness are reported in approximately 5% of patients.
There is evidence that guanethidine (the active ingredient contained in Ismelin) may interfere with ejaculation by inhibiting contraction of the seminal vesicle, ampula and ductus deferens.
Large studies report sexual impotence as a relatively uncommon genitourinary complaint, occurring in only approximately 2% of male patients. Smaller studies, where specific questions were asked of male patients reveal an incidence of impotence as high as 60%. Delayed or retrograde ejaculation and decreased sperm counts are reported. Impotence appears to be reversible upon discontinuation of therapy or reduction in dosage.
A relatively common respiratory system complaint, nasal stuffiness in up to 30% of patients, is related to increased parasympathetic tone. Rare reports of dyspnea or exertion unaccompanied by other signs or symptoms of congestive heart failure are associated with guanethidine (the active ingredient contained in Ismelin)
In one study, 58% of patients with or without preexisting elevated BUN developed an increase in the BUN during guanethidine (the active ingredient contained in Ismelin) therapy. The study did not, however, quantify the rise in BUN, attempt to make an association with the degree of blood pressure control, or attempt to measure other parameters of renal function.
Because guanethidine (the active ingredient contained in Ismelin) does not affect the central nervous system, neurologic side effects are notably either absent or infrequent. Insomnia and weakness are occasionally reported more often with guanethidine than with placebo.
Hypersensitivity reactions are not associated with guanethidine (the active ingredient contained in Ismelin)
More about Ismelin (guanethidine)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.